CARB-X FUNDS MICROBION TO DEVELOP INHALED DRUG TO TREAT CYSTIC FIBROSIS-RELATED LUNG INFECTIONS

  29 May 2020

CARB-X announced today it is awarding Microbion Corporation of Bozeman, MT, USA, up to $6.1 million plus up to $5.4 million more if certain project milestones are met, to develop its anti-infective drug pravibismane for the treatment of cystic fibrosis (CF)-related pulmonary infections.

The research project is CARB-X’s first award for the development of an inhaled antibiotic to treat chronic lung infections and potentially infections in people living with CF.

“Microbion’s new class of anti-infective represents a novel drug that has shown potent activity against antibiotic-resistant bacterial pathogens and the biofilms these pathogens produce. Microbion’s pravibismane, if successful and eventually approved for use in patients, has the potential to be a critical new weapon in the fight against chronic and resistant infections,” said Erin Duffy, Chief of Research and Development of CARB-X.

The funding from CARB-X, along with a separate award announced today of up to $5.6 million from the Cystic Fibrosis Foundation, will help Microbion further explore the potential of pravibismane to kill drug-resistant bacteria and their biofilms and test its safety as an inhaled treatment for people with CF. If the results are positive, the anti-infective could next move into clinical development to test its effectiveness.

Further reading: CARB-X
Author(s): CARB-X
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!